AMRX vs PH · P/E 44, rev $2.79B vs P/E 28, rev $19.85B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the AMRX and PH stock pages for the full models.
Not investment advice.